20.89
Schlusskurs vom Vortag:
$20.68
Offen:
$20.65
24-Stunden-Volumen:
2.33M
Relative Volume:
0.61
Marktkapitalisierung:
$3.82B
Einnahmen:
$644.86M
Nettoeinkommen (Verlust:
$196.05M
KGV:
21.29
EPS:
0.9812
Netto-Cashflow:
$317.50M
1W Leistung:
+2.15%
1M Leistung:
+10.12%
6M Leistung:
-52.31%
1J Leistung:
-62.67%
Doximity Inc Stock (DOCS) Company Profile
Firmenname
Doximity Inc
Sektor
Branche
Telefon
(650) 549-4330
Adresse
500 THIRD STREET, SUITE 510, SAN FRANCISCO
Compare DOCS vs VEEV, BTSG, TEM, HQY, HNGE
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
DOCS
Doximity Inc
|
20.89 | 3.78B | 644.86M | 196.05M | 317.50M | 0.9812 |
|
VEEV
Veeva Systems Inc
|
163.38 | 26.34B | 3.32B | 941.65M | 1.64B | 5.6161 |
|
BTSG
Brightspring Health Services Inc
|
64.14 | 12.58B | 13.65B | 169.86M | 412.12M | 1.0758 |
|
TEM
Tempus Ai Inc
|
50.56 | 9.39B | 1.36B | -302.91M | -219.93M | -1.7182 |
|
HQY
Healthequity Inc
|
85.66 | 7.27B | 1.34B | 230.70M | 440.96M | 2.6695 |
|
HNGE
Hinge Health Inc
|
67.81 | 5.29B | 646.34M | -512.40M | 202.76M | -6.6871 |
Doximity Inc Stock (DOCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Herabstufung | Truist | Buy → Hold |
| 2026-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2026-02-09 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2026-02-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2026-01-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-01-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-01-08 | Hochstufung | Truist | Hold → Buy |
| 2025-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-11-21 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-11-13 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2025-10-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-10-01 | Herabstufung | Goldman | Neutral → Sell |
| 2025-07-09 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-06-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-02-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-12-20 | Eingeleitet | Stephens | Equal-Weight |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-11-15 | Eingeleitet | Goldman | Neutral |
| 2024-11-14 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-11-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-11-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-11-08 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-09 | Hochstufung | Needham | Hold → Buy |
| 2024-07-18 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2024-04-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2024-01-02 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-08-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-08-09 | Herabstufung | Needham | Buy → Hold |
| 2023-08-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-24 | Eingeleitet | Evercore ISI | In-line |
| 2022-10-13 | Eingeleitet | BTIG Research | Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-28 | Eingeleitet | Berenberg | Buy |
| 2022-05-18 | Bestätigt | BofA Securities | Neutral |
| 2022-05-18 | Bestätigt | Goldman | Buy |
| 2022-05-18 | Bestätigt | Guggenheim | Buy |
| 2022-05-18 | Bestätigt | Jefferies | Buy |
| 2022-05-18 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Bestätigt | Needham | Buy |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-04 | Eingeleitet | BofA Securities | Neutral |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2021-12-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-11-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-10 | Bestätigt | Canaccord Genuity | Buy |
| 2021-11-10 | Bestätigt | Goldman | Neutral |
| 2021-11-10 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Bestätigt | Needham | Buy |
| 2021-11-10 | Bestätigt | Piper Sandler | Overweight |
| 2021-08-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-19 | Eingeleitet | Goldman | Neutral |
| 2021-07-19 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-07-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-07-19 | Eingeleitet | Raymond James | Outperform |
| 2021-07-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-19 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Doximity Inc Aktie (DOCS) Neueste Nachrichten
Doximity, Inc. (DOCS) Stock Analysis: Exploring a 26.85% Potential Upside in Health Information Services - DirectorsTalk Interviews
Responsive Playbooks and the DOCS Inflection - Stock Traders Daily
Y Intercept Hong Kong Ltd Invests $9 Million in Doximity, Inc. $DOCS - MarketBeat
Doximity, Inc. $DOCS Shares Purchased by Rhenman & Partners Asset Management AB - MarketBeat
Doximity (DOCS) up 11.2% since last earnings report: Can it continue? - MSN
Doximity: Cheaper, But Growth Is Still Missing (NYSE:DOCS) - Seeking Alpha
Is Doximity Struggling After Revenue Miss? - Kalkine Media
Doximity (DOCS) Up 11.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Top Doximity (DOCS) Competitors 2026 - MarketBeat
DOCS Investors Have Opportunity to Join Doximity, Inc. Fraud Inv - GuruFocus
DOCS Investors Have Opportunity to Join Doximity, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc.DOCS - PR Newswire
Doximity interim PAO Sitaram Siddharth sells $49,882 in shares By Investing.com - Investing.com Canada
Doximity interim PAO Sitaram Siddharth sells $49,882 in shares - Investing.com UK
symbol__ Stock Quote Price and Forecast - CNN
Doximity (DOCS) interim PAO trades shares under 10b5-1 plan, exercises options - Stock Titan
AI Margin Pressure And Legal Probe Might Change The Case For Investing In Doximity (DOCS) - simplywall.st
Doximity hits an all-time low after Q4 results; KeyBanc downgrades - MSN
[144] Doximity, Inc. SEC Filing - Stock Titan
Capital World Investors Has $250.40 Million Holdings in Doximity, Inc. $DOCS - MarketBeat
DOCS (NASDAQ: DOCS) Form 144 reports 2,444-share sale via exercise - Stock Titan
Doximity shares drop 23% after missing revenue targets and AI investment warning - Pluang
Doximity, Inc. (DOCS) Stock Analysis: Exploring a 22.15% Potential Upside in the Healthcare Information Sector - DirectorsTalk Interviews
Doximity(DOCS) Stock Options Chain | Quotes & News - Moomoo
Law firm investigates Doximity officers for possible shareholder rights breaches - Pluang
BofA Securities Maintains Doximity(DOCS.US) With Buy Rating, Cuts Target Price to $38 - Moomoo
DOCS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
2026-06-05 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Doximity, Inc. (DOCS) and Encourages Shareholders to Learn More About the Investigation | NYSE:DOCS | Press Release - Stockhouse
Doximity stock falls on Q4 earnings miss, revenues beat, margins down - MSN
Legal & General Group Plc Sells 54,024 Shares of Doximity, Inc. $DOCS - MarketBeat
BNP Paribas Financial Markets Raises Position in Doximity, Inc. $DOCS - MarketBeat
Doximity, Inc. (DOCS) Investigation: Bronstein, Gewirtz & Grossma - The National Law Review
Doximity, Inc. (DOCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Doximity (NYSE:DOCS) Downgraded by Zacks Research to Strong Sell - MarketBeat
Workday and Doximity shares are soaring, what you need to know - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Doximity, Inc. (DOCS) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Understanding the Setup: (DOCS) and Scalable Risk - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Encourages Doximity, Inc. (DOC - The National Law Review
Assessing Doximity (DOCS) Valuation After A Year Of Weak Share Price Performance - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Doximity, Inc. (DOCS) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Doximity, Inc. (DOCS) And Encourages Shareholders to Connect - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Doximity, Inc. (DOCS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Doximity, Inc. (DOCS) Stock Analysis: Evaluating The 17.52% Upside Potential For Investors - DirectorsTalk Interviews
DOCS Stock Price, Quote & Chart | DOXIMITY INC-CLASS A (NYSE:DOCS) - ChartMill
Doximity (DOCS) Stock Trends and Sentiment 2026 $DOCS - MarketBeat
Doximity Stock Just Got Crushed. Is This a Rare Chance to Buy a High-Quality Growth Company on Sale? - AOL.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Doximity, Inc. (DOCS) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Doximity, Inc. (DOCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Workday and Doximity Shares Are Soaring, What You Need To Know - Yahoo Finance
DOCS Q1 2026 Earnings: EPS Misses Estimates, Stock Rises on Strategic ProgressFinal Results - thelegaladvocate.com
Finanzdaten der Doximity Inc-Aktie (DOCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):